Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes

Código QR

Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes

Patricia Udaondo,1,2 Ana Hervas-Ontiveros,1,2 Amir Rosemblatt,3,4 Salvador Garcia-Delpech1,2 1Ophthalmology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; 2Aiken Prevencción y Cirugía Ocular, Valencia, Spain; 3Department of Ophthalmology, Tel-Aviv Sourasky Medical Center, T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Udaondo P, Hervas-Ontiveros A, Rosemblatt A, Garcia-Delpech S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	diabetic macular edema dexamethasone intravitreal implant ozurdex best corrected visual acuity central macular thickness. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9211288ec58c4a26884561a71f4512db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective
por: Urbančič M, et al.
Publicado: (2019)

A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
por: Vadalà M, et al.
Publicado: (2020)

Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy
por: Chiara Altana, et al.
Publicado: (2021)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Macular edema resolution assessment with implantable dexamethasone in diabetic retinopathy (MERIT): a pilot study
por: Chhablani J, et al.
Publicado: (2018)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
por: Dweikat A, et al.
Publicado: (2021)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho J, et al.
Publicado: (2019)

Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series
por: Singer MA, et al.
Publicado: (2016)

Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
por: Al-Latayfeh M, et al.
Publicado: (2021)

Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
por: Javier Obis, et al.
Publicado: (2021)

Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
por: Zola M, et al.
Publicado: (2017)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
por: Kaya C, et al.
Publicado: (2019)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
por: Van Aken E, et al.
Publicado: (2020)

Effects of Repeated Intravitreal Injections of Dexamethasone Implants on Intraocular Pressure: A 4-Year Study
por: Pacella E, et al.
Publicado: (2020)

Multicenter, Prospective, Randomized Study of Dexamethasone Intravitreal Implant in Patients with Center-Involved Diabetic Macular Edema in the Asia-Pacific Region
por: Wei W, et al.
Publicado: (2021)

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
por: Massin P, et al.
Publicado: (2016)

EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
por: Ume Sughra, et al.
Publicado: (2021)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
por: Dugel PU, et al.
Publicado: (2016)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine I, et al.
Publicado: (2017)

Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review
por: Wallsh J, et al.
Publicado: (2020)

Letter to the Editor Regarding the “Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis” Article [Letter]
por: Taylor K, et al.
Publicado: (2020)

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
por: Elbarky AM
Publicado: (2020)

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
por: Joshi L, et al.
Publicado: (2016)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
por: Campos Polo R, et al.
Publicado: (2018)

Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
por: Michalska-Małecka K, et al.
Publicado: (2016)

Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization
por: Figueira J, et al.
Publicado: (2021)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Jia-Kang Wang, et al.
Publicado: (2018)

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye
por: Ren Aoki, et al.
Publicado: (2021)

The effects of repeated Ozurdex injections on ocular hypertension
por: Bahadorani S, et al.
Publicado: (2018)

Clinical Experience in the Administration of Intravitreal Injection Therapy at a Tertiary University Hospital in Jordan During the COVID-19 Lockdown
por: Saleh OA, et al.
Publicado: (2020)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
por: Chen YX, et al.
Publicado: (2020)

Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial
por: Fonseca ALA, et al.
Publicado: (2019)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
por: Andrzej Grzybowski, et al.
Publicado: (2021)

Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review
por: Nithianandan H, et al.
Publicado: (2020)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
por: Hall J
Publicado: (2016)

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study
por: Pece A, et al.
Publicado: (2016)